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Aims: The MRC RT01 trial used conformal radiotherapy to the prostate, a method that reduces the volume of normal
tissue treated by 40e50%. Because of the risk of geographical miss, the trial used portal imaging to examine whether
treatment delivery was within the required accuracy.
Material and methods: In total, 843 patients were randomly assigned to receive 64 Gy in 32 fractions over 6.5 weeks or
74 Gy in 37 fractions over 7.5 weeks. Field displacements and corrections were recorded for all imaged fractions.
Displacement trends and their association with time, disease and treatment set-up characteristics were examined using
univariate and multivariate analyses. A Radiographer Trial Implementation Group (RTIG) was set up to inform the quality
assurance process and to promote the development of best practice.
Results: Treatment isocentre positioning was within 5 mm in every direction on 6238 (83%) of the 7535 fractions
imaged. In total, 532 (81%) of 695 included patients had at least one R 3mm displacement and 415 (63%) had at least
one R 5mm displacement. Univariate, multivariate and stepwise models of R 5mm displacements showed an increased
likelihood of displacement in weeks 1 and 2 with low melting point alloy (LMPA) blocks compared with multileaf
collimators, film verification compared with electronic portal imaging (EPI) and increased number of fractions imaged.
Except for LMPA, this was also seen for R 5mm displacements in weeks 3e6.
Conclusions: Accurate conformal treatment was delivered. The use of EPI was associated with increased reported
accuracy. The RTIG was a crucial part of the quality assurance process. Stanley, S. et al. (2008). Clinical Oncology 20,
582—590
ª 2008 The Royal College of Radiologists. Published by Elsevier Ltd.
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Open access under CC BY license.Introduction
Conformal radiotherapy is now a standard treatment for
localised carcinoma of the prostate [1]. The MRC RT01 trial
investigated the efficacy and safety of delivering dose-
escalated conformal field radiotherapy for prostate cancer
[2e4]. Between January 1998 and December 2001, 843
patients at 19 radiotherapy centres (17 in the UK) were
randomised to receive either the standard dose (64 Gy/32
fractions) or an escalated dose (74 Gy/37 fractions). This
was given as 64 Gy to the prostate and seminal vesicles
(phase I) according to risk group, with or without a 10 Gy0936-6555/08/200582þ09 $35.00/0 ªboost to the prostate only (phase II). Compared with
conventional radiotherapy, conformal radiotherapy reduces
the volume of normal tissue treated by 40e50% [5].
However, with this comes the risk of geographical miss
due to set-up uncertainties. Therefore, regular portal
imaging and image analysis was carried out to ensure that
treatment delivery was within the margin of tolerance.
Displacements were identified and corrections confirmed
according to the protocol.
The trial quality assurance group initiated a dosimetric
and geometric quality assurance review process [6].
Completion of a quality assurance questionnaire was2008 The Royal College of Radiologists. Published by Elsevier Ltd.
Open access under CC BY license.
Table 1 e Methods used for treatment and verification by centre
Centre*
Number
of fields
Beam
modification
Image
type
Analysis
method
2 Four-field MLC EPI Software
3 Both Both Both Software
4 Four-field MLC EPI Software
7 Three-field MLC EPI Software
8 Four-field MLC EPI Software
9 Three-field MLC Film Manual
10 Three-field MLC EPI Software
11 Three-field Both EPI Software
15 Three-field LMPA Film Manual
16 Four-field MLC Film Manual
17 Three-field MLC EPI Software
18 Four-field LMPA EPI Software
19 Three-field MLC EPI Manual
20 Four-field LMPA Film Manual
22 Three-field LMPA Film Manual
23 Three-field MLC EPI Software
25 Three-field Both Film Manual
30 Four-field MLC Both Software
MLC, multileaf collimator; LMPA, low melting point alloy; EPI,
electronic portal imaging. *Sites have been coded. The same codes
are used in Tables 1 and 2.
583REPRODUCIBILITY OF CONFORMAL RADIOTHERAPY IN PROSTATE CANCERa prerequisite to participation. The validity of the
questionnaire responses was confirmed by visits to all UK
centres during the trial where under experimental condi-
tions using a phantom a low and acceptable variation in
dosimetric and geometric uncertainty was indicated [7].
The quality assurance processes showed that all centres
could deliver and verify conformal radiotherapy to the
standard required to participate in the trial.
A Radiographer Trial Implementation Group (RTIG) in-
volving radiographers from all UK participating centres was
established to co-ordinate clinical aspects of the trial
quality assurance process. RTIG roles included the imple-
mentation of radiographer-led portal imaging analysis,
ensuring that data on treatment accuracy were collected
according to protocol, monitoring technique accuracy in
treatment delivery and developing and sharing best practice
methods for the radiotherapy process. Displacement and
correction data were collected on a radiographers’ log case
report form for each patient [2,8]. This paper uses the
displacement and correction data submitted by the partici-
pating centres to assess the variability in the patient set-up
and to comment on the accuracy of conformal radiotherapy
treatments delivered during only phase I of trial radiother-
apy, which was common to all trial patients.
Materials and Methods
Of 831 patients who started radiotherapy, 824 had
radiographer logs returned. However, one participating
centre used online imaging to verify and correct before
each fraction and so no displacement data were submitted.
Therefore, patients from this centre were excluded from
these analyses and displacement and correction data for
695 patients were analysed.Treatment TechniqueThe trial protocol allowed for three- or four-field tech-
niques using either multileaf collimators (MLCs) or low
melting point alloy (LMPA) shaped blocks (Table 1). All
fields were to be treated daily on a linear accelerator of
R 5 MV. All patients were treated supine with locally
standard immobilisation.
Computed Tomography Planning
and Safety Margins
Gross tumour volume and clinical target volume were to be
defined on computed tomography scans taken at 5 mm
intervals from the bottom of the sacro-iliac joints to the
penile urethra (1 cm below ischial tuberosities). The
clinical target volume was defined as gross tumour
volumeþ 0.5 cm and planning target volume with a three-
dimensional safety margin around the clinical target
volume of 0.5e1.0 cm. Each participating centre could
specify their own planning target volume margin within this
range to account for local set-up uncertainties. No oral,
rectal or intravenous contrast agents were allowed.Verification Protocol, Radiographers’ Log
Displacement and Correction DataAlthough in 1998 electronic portal imaging (EPI) was
a recent innovation, used in relatively few UK centres, it
is now an established method for determining set-up
accuracy [9e13]. For the RT01 trial, an image-based
verification protocol was devised to measure set-up
displacements and corrections at regular intervals through-
out the course of treatment. The radiographers’ log used in
a previous single-centre pilot study [14] was adapted to
record displacement and correction data.
The trial imaging protocol defined a field placement
tolerance of 3 mm in any field axis. Positioning errors
R 5 mm were considered unacceptable and were required to
haveacorrectionappliedbeforethesubsequent fractionbeing
delivered. Images taken,measurements and correctionsmade
and accuracy on the fraction after correction were recorded
on the radiographers’ log for each fraction imaged. Displace-
ments were recorded for lateral, longitudinal and vertical
directions from anterior/posterior and lateral/oblique views.
Rotational errors were not recorded as not all centres were
capable of accurately quantifying this type of error.
The trial imaging protocol also defined image frequency
and megavoltage images were acquired on at least two
consecutive fractions during the first week of treatment
and once weekly thereafter, with repeat images after any
corrections to verify the change. The timing of the image
acquisition (before, during or after treatment delivery) was
not defined in the protocol. All megavoltage images were
compared with either a simulator film or a digitally
reconstructed radiograph to determine displacements.
The method of image registration used was the choice of
584 CLINICAL ONCOLOGYthe centre. As both film and electronic images were
acquired, manual (light box) or software analysis methods
were used to measure displacements.Statistical Considerations0
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Size of corrections and displacements by directionThe direction and size of displacements and corrections
were summarised according to the three cardinal axes.
Fractions were classified as having a R 3 mm or R 5 mm
displacement or correction in any one dimension (direction)
or over all three dimensions. The number of fractions with
and without a displacement, and the number of patients
with and without displacement in a given week of
treatment were summarised graphically.
It was anticipated that displacements might occur
throughout treatment, that set-up errors would most
probably occur in the first 2 weeks of treatment, and that
corrections would prevent systematically occurring errors
thereafter. Univariate and multivariate ordered logistic
regression models were run for: patients with at least one
R 3 mm displacement; patients with at least one R5 mm
displacement; data in weeks 1 and 2; data in weeks 3
onwards. The effects of disease and treatment set-up factors
were investigated. The risk group, which was calculated from
T-stage, differentiation and prostate-specific antigen, was
a stratification factor for the trial randomisation. Therefore,
this was included in the multivariate analyses and, conse-
quently, T-stage and differentiation were not included in the
multivariate analyses (prostate-specific antigen was not
included in either uni- or multivariate analyses). The models
considered the impact baseline bladder symptoms, which
were dichotomised to none or some according to the Royal
Marsden Hospital scale [3]. The treatment centre was not
included as a variable in the analyses because the number of
centres was too large and there were too many variables
within the data from each centre. The allocated dose group
was included in the univariate analyses for completeness and
assurance, but excluded from the multivariate analyses:
these analyses include only data from phase I of treatment,
which was identically planned regardless of the allocated
trial treatment (treatment differed in terms of the inclusion
or not of phase II treatment). Therefore, any effect from the
dose group could only be due to chance. There was no
evidence of an effect in the univariate analyses for allocated
dose group and the factor was not included in the
multivariate model. Patients were excluded from the
(ordered) logistic regression analyses where imaging was
carried out using both EPI and film (n¼ 41) or a six-field
technique (n¼ 1) was used. Therefore, data were available
for these analyses from 657 of 695 patients.
All analyses were carried out using the statistical package
Stata 9 (Stata Corporation, College Station, TX, USA).displacements corrections
Data for imaged fractions only
0-2mm 3-4mm 5mm+
ResultsAbbreviations: long=longitudinal, lat=lateral, vert=verticalTranslational DisplacementsFig. 1 e Size and direction of reported corrections and displace-
ments in imaged fractions.Displacements R 3 mm were recorded for 2797 (37%) of the
7535 fractions reported. The displacements were similarlydistributed across the three directions (Fig. 1) with no good
evidence of a difference from zero. The absolute lateral
mean displacement was 0.2 mm to the right (standard
deviation 2.2 mm); the longitudinal absolute mean dis-
placement was 0.2 mm superiorly (standard deviation
2.4 mm); and the vertical absolute mean displacement
was 0.1 mm anteriorly (standard deviation 1.2 mm).
Treatment was delivered within 5 mm of the planned
position in every dimension for 6238 (83%) of the 7535
fractions reported, based on the position of bony land-
marks. Table 2 shows data by centre. In total, 532 (81%) of
695 patients included had at least one R 3 mm displace-
ment and 415 (63%) had at least one R 5 mm displacement.
The number of fractions imaged reduced over the
treatment weeks. This is also reflected in a decrease in
the number of patients with fractions imaged. This cannot
be explained by patients stopping treatment early. The
proportion of reported displacements in a given treatment
week is summarised in Fig. 2. The first two weeks had
a higher reported proportion of patients with displaced
fractions. A similar pattern was seen for the proportion of
displacements of R 3 mm and R 5 mm. There were fewer
corrections than displacements, but the same trend
towards decreased corrections carried out by week of
treatment was observed (data not shown).Association of Disease and Treatment Set-up
Characteristics with DisplacementsRadiotherapy delivery methods were used in only a small
number of combinations across the trial centres and
associations were present between the beam modification
and treatment verification methods. For example, 407
(96%) patients whose treatment was verified with EPI had
beam modification with MLC, whereas this was the case for
only 71 (31%) patients verified with film. As expected, the
number of images taken was much higher for patients
imaged with EPI (mean 27.8, standard deviation 9.0) rather
than film (mean 19.6, standard deviation 5.2; P! 0.001)
Table 2 e Corrections and displacements overall
Radiotherapy
treatment
centre*
Patients
with data
Total fractions
reported
Fractions reported
per patient
Total films/
images
Displaced fractions
reported [n (%)]y
Corrected fractions
reported [n (%)]y
Median Quartiles 3 mmþ 5 mmþ 3 mmþ 5 mmþ
2 49 653 13 12e14 1396 246 (38) 38 (6) 11 (2) 3 (0)
3 149 1614 11 9e12 3259 983 (61) 558 (35) 173 (11) 48 (3)
4 35 376 10 10e12 1193 228 (61) 137 (36) 21 (6) 8 (2)
7 22 299 14 12e15 702 102 (34) 41 (14) 34 (11) 7 (2)
8 40 481 11 10e14 968 169 (35) 68 (14) 10 (2) 2 (0)
9 14 137 10 9e11 213 63 (46) 22 (16) 11 (8) 1 (1)
10 40 433 11 10e12 1054 123 (28) 40 (9) 10 (2) 3 (1)
11 139 1518 11 9e13 3204 495 (33) 171 (11) 127 (8) 33 (2)
15 5 29 8 2e8 60 3 (10) 1 (3) 0 (0) 0 (0)
16 31 280 9 8e10 528 85 (30) 49 (18) 35 (13) 19 (7)
17 19 152 8 7e9 364 64 (42) 33 (22) 2 (1) 1 (1)
18 3 23 8 6e9 73 6 (26) 0 (0) 1 (4) 0 (0)
19 92 1028 11 10e12 3213 38 (4) 33 (3) 34 (3) 31 (3)
20 7 61 8 8e10 139 5 (8) 1 (2) 3 (5) 1 (2)
22 22 177 8 7e9 372 9 (5) 2 (1) 1 (1) 1 (1)
23 3 29 10 9e10 87 19 (66) 6 (21) 0 (0) 0 (0)
25 2 23 12 11e12 44 16 (70) 8 (35) 6 (26) 6 (26)
30 23 222 10 8e12 524 143 (64) 89 (40) 11 (5) 11 (5)
Total 695 7535 11 9e12 17 393 2797 (37) 1297 (17) 490 (7) 175 (2)
*Sites have been coded. The same codes are used in Tables 1 and 2. y3 mmþ displacements include 5 mmþ displacements.
585REPRODUCIBILITY OF CONFORMAL RADIOTHERAPY IN PROSTATE CANCERand also for MLC (mean 26.8, standard deviation 9.6) over
LMPA (mean 21.0, standard deviation 4.4) as the beam
modification method (P! 0.001).
In the univariate models of R 3 mm reported displace-
ments in weeks 1 and 2 (Table 3), there was evidence of an
increased likelihood of a displacement being reported with
higher T-stage, lower age, moderate risk group, beam
modification with LMPA, treatment verification with film,
four phase I fields and increasing number of imaged
fractions reported. In the multivariate model of R 3 mm
reported displacements in weeks 1 and 2, lower age,
moderate risk group, treatment verification with film and
an increased number of fractions imaged were significant.
In weeks 3e6 (Table 4), only an increasing number of
fractions reported and treatment verification with film
were associated with increased occurrence of at least one
reported displacement.
In the univariate, multivariate and stepwise models of
R 5 mm reported displacements there was evidence of an
increased likelihood of a displacement across weeks 1e2
and 3e6 with film and an increased number of fractions
imaged. LMPA beam modification was associated with
increased displacements in all the models except multivar-
iate weeks 3e6 (Tables 5 and 6).
There was no evidence of an effect from the allocated
trial treatment, actual dose given or the presence of
baseline bladder symptoms.
Discussion
MRC RT01 was a pragmatic trial that accompanied the
initiation of conformal radiotherapy for prostate cancer inmany UK centres. The results of external measurements of
displacements and associated corrections show that it is
possible to give accurate and reproducible treatment.
There may be some factors that affect accuracy.
The requirement to correct all errors R 5 mm at or
before the next fraction was applied inconsistently, as
centres had differing local correction practices. This will
have influenced the number of displacements and correc-
tions reported. Only one centre corrected most of the
displacements reported, although the number of displace-
ments reported by this centre was comparatively small. In
other centres, corrections were only made after two
fractions showing errors of O3 or O5 mm had been
measured. This would explain why some centres have more
displacements recorded than corrections and is particularly
relevant for weeks 2e6, as any systematic errors should
have been identified and corrected during week 1 (or at
least by week 2). Displacements are more useful here than
corrections because displacements were more objective
across the trial, whereas corrections required human
interpretation and intervention: there were no consistent
trial-wide guidelines on how these should be applied. The
method of correcting only after errors were seen on two or
more fractions is supported by several studies, suggesting
that, in order to optimise the correction in terms of
identifying the systematic component, repeated imaging is
required [15e17]. Assessment of random and systematic
errors should be included for future trials.
Local policies for the magnitude of the correction ranged
between correcting 50 and 100% of the measured dis-
placements. For this pragmatic trial it was appropriate to
allow centres to be comfortable with their own verification
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Data table for Figure 2
Graph Week Week 1 Week 2 Week 3 Week 4 Week 5 Week 6
Panel Displacements n % n % n % n % n % n %
A 3mm – fractions 987 39 476 40 363 37 311 34 317 36 273 34
B 3mm – patients 453 66 303 48 251 40 233 37 234 38 209 36
C 5mm – fractions 490 19 218 18 181 19 130 14 129 14 120 15
D 5mm – patients 286 41 170 27 129 20 102 16 102 17 100 17
n: rows 1 and 3 = number of reported fractions with displacements
n: rows 2 and 4 = number of patients with at least one displacements
%: rows 1 and 3 = number of reported fractions with a displacement expressed as a % of the reported fractions
%: rows 2 and 4 = number of patients with at least reported fraction a with displacements as a % of the patients
 with at least one reported fractions 
Fig. 2 e Four-way panel graphs of displacements by week.
586 CLINICAL ONCOLOGYpolicies as many were just starting to use EPI and
associated software. To have been more specific may have
resulted in poor compliance. However, for any new trial,
a more detailed correction policy should be specified.
Deviation from the weekly imaging protocol was identified
in that the number of patients imaged in a given week was
often less than the number of patients still undergoing
radiotherapy. The quality assurance visits identified that at
least one centre had interpreted the protocol incorrectly
and had not imaged weekly during phase 1 for patients
treated early in the trial.The method used to image also had implications. Film
verification increased the likelihood of at least one
reported displacement compared with EPI, despite the
fact that film was associated with significantly fewer
displaced fractions reported than EPI and fewer images
taken during treatment than EPI. The methods used to
measure displacement may also have had an effect. The
difficulty in the evaluation of lateral images was highlighted
by RTIG. Perera et al. [18] found that human observers have
difficulty in identifying displacements of !5 mm when
using manual methods. It should be noted that where EPI
Table 3 e Patients with one or more displacement of at least 3 mm in weeks 1e2: univariate and multivariate logistic regression models
Category*
Data Univariate models Multivariate models
Miss n
3 mmþ
displacement OR (95% CI) z P n OR (95% CI) z P
T-stage 2 655 178 1.65 (1.26, 2.17) 3.61 !0.001 645 e e e e
Differentiation 0 657 179 0.81 (0.57, 1.15) 1.18 0.240 e e e e e
Age (quartiles) 0 657 179 0.89 (0.76, 1.04) 1.52 0.129 e 0.84 (0.71, 0.99) 2.11 0.035
Risk group 0 657 179 1.41 (0.98, 2.02) 1.86 0.063 e 1.49 (1.02, 2.19) 2.06 0.039
Allocated treatment 0 657 179 1.04 (0.74, 1.46) 0.21 0.836 e 1.15 (0.80, 1.64) 0.74 0.461
Dose group 0 657 179 1.00 (0.26, 3.82) 0.00 0.998 e e e e e
Beam modification 6 651 179 1.41 (0.94, 2.11) 1.65 0.098 e 1.35 (0.74, 2.44) 0.98 0.326
Treatment verification 2 655 179 1.38 (0.96, 2.00) 1.73 0.084 e 2.59 (1.41, 4.75) 3.08 0.002
Phase I fields 2 655 179 1.59 (1.10, 2.30) 2.49 0.013 e 1.40 (0.95, 2.07) 1.72 0.086
Fractions imaged 0 657 179 1.99 (1.50, 2.64) 4.80 !0.001 e 1.47 (1.29, 1.69) 5.63 !0.001
Baseline bladder symptoms 6 651 179 1.05 (0.74, 1.50) 0.28 0.776 e 1.06 (0.73, 1.54) 0.29 0.770
T-stage and differentiation were not included in the multivariate models because they were jointly represented in the risk group. LMPA, low
melting point alloy; MLC, multileaf collimator; EPI, electronic portal imaging. *Category (reference category is depicted in bold):
T-stage¼ T1 vs T2 vs T3 Differentiation¼Good vs moderate vs poor (based on differentiation or Gleason sum score, where available);
Age¼ 46e62, 63e66, 67e70, 71 and over; Risk group¼ Low vs moderate (trial stratification factor); Allocated treatment¼ 74Gy/37 fractions
vs 64 Gy/32 fractions; Beam modification¼MLC vs LMPA; Treatment verification¼ EPI vs film; Phase I fields¼ three vs four (patients with six
phase I fields were excluded); Total dose¼!64Gy vs 64 Gyþ; Number of fractions reported¼ 0e3 vs 4e6 vs 7þ.
587REPRODUCIBILITY OF CONFORMAL RADIOTHERAPY IN PROSTATE CANCERwas used in this trial, the software analysis was not based
on fully automatic registration.
The displacement data are comparable with those
reported in several smaller studies of prostate conformal
radiotherapy reproducibility [19e27], where immobilisa-
tion methods have been compared. A broad range of
displacements was seen between the participating centres
and this can be linked to their practice. Further discussion
on the methods used by participating centres is discussed in
other RT01 publications with recommendations [6,8].Table 4 e Patients with one or more displacement of at least 3mm in w
Category*
Data Univa
Miss n
3 mmþ
displacement OR (95% C
T-stage 2 639 226 1.34 (1.04, 1.
Differentiation 0 641 226 0.76 (0.55, 1.
Age (quartile) 0 641 226 1.01 (0.87, 1.
Risk group 0 641 226 1.56 (1.11, 2.
Allocated treatment 0 641 226 1.14 (0.83, 1.
Dose group 0 641 226 0.45 (0.10, 2.
Beam modification 5 636 224 2.24 (1.50, 3.
Treatment verification 1 640 226 2.05 (1.43, 2.
Phase I fields 1 640 226 1.92 (1.36, 2.
Fractions imaged 0 641 226 3.98 (2.97, 5.
Baseline bladder symptoms 6 635 226 0.97 (0.69, 1.
T-stage and differentiation were not included in the multivariate models
melting point alloy; MLC, multileaf collimator; EPI, electronic porta
T-stage¼ T1 vs T2 vs T3; Differentiation¼Good vs moderate vs poor (
Age¼ 46e62, 63e66, 67e70, 71 and over; Risk group¼ Low vs moderate (
vs 64 Gy/32 fractions; Beam modification¼MLC vs LMPA; Treatment
dose¼!64Gy vs 64 Gyþ; Number of fractions reported¼ 0e3 vs 4e5 vOnly one centre was using clinician-led portal image
analysis for the trial, although several undertook clinician
review after radiographer-led analysis. For most radiogra-
phers, this trial provided an opportunity to develop skills in
portal imaging and further showed that this is a role that
can be successfully undertaken by radiographers [28]. The
existence of RTIG provided an unprecedented opportunity
for radiographers from a number of centres to discuss
treatment delivery, verification and reproducibility issues
and to learn from the experiences and practices of otherseeks 3e6: univariate and multivariate logistic regression models
riate models Multivariate models
I) z P n OR (95% CI) z P
72) 2.28 0.023 630 e e e e
07) 1.58 0.113 e e e e e
17) 0.13 0.900 e 0.96 (0.82, 1.13) 0.47 0.638
19) 2.54 0.011 e 1.32 (0.90, 1.95) 1.43 0.153
58) 0.81 0.420 e 1.13 (0.78, 1.62) 0.65 0.518
16) 0.99 0.321 e e e e e
34) 3.97 !0.001 e 1.00 (0.53, 1.86) 0.01 0.991
93) 3.91 !0.001 e 2.01 (1.14, 3.56) 2.4 0.016
71) 3.70 !0.001 e 1.27 (0.86, 1.88) 1.22 0.222
33) 9.28 !0.001 e 1.74 (1.53, 1.98) 8.29 !0.001
37) 0.15 0.882 e 0.92 (0.63, 1.35) 0.42 0.677
because they were jointly represented in the risk group. LMPA, low
l imaging. *Category (reference category is depicted in bold):
based on differentiation or Gleason sum score, where available);
trial stratification factor); Allocated treatment¼ 74Gy/37 fractions
verification¼ EPI vs film; Phase I fields¼ three vs four; Total
s 6e8 vs 9þ.
Table 5 e Patients with one or more displacement of 5mm in weeks 1e2: univariate and multivariate logistic regression models
Category*
Data Univariate models Multivariate models
Miss n
3 mmþ
displacement OR (95% CI) z P n OR (95% CI) z P
T-stage 2 655 318 1.07 (0.85, 1.36) 0.59 0.558 645 e e e e
Differentiation 0 657 320 0.81 (0.59, 1.12) 1.28 0.202 e e e e e
Age (quartile) 0 657 320 1.02 (0.88, 1.17) 0.23 0.819 e 0.98 (0.84, 1.14) 0.28 0.778
Risk group 0 657 320 0.98 (0.71, 1.36) 0.12 0.901 e 1.07 (0.75, 1.52) 0.37 0.708
Allocated treatment 0 657 320 0.83 (0.61, 1.12) 1.21 0.225 e 0.91 (0.66, 1.26) 0.57 0.566
Dose group 0 657 320 0.60 (0.17, 2.06) 0.82 0.414 e e e e e
Beam modification 6 651 319 1.72 (1.21, 2.45) 3.03 0.002 e 1.85 (1.09, 3.14) 2.29 0.022
Treatment verification 2 655 319 1.49 (1.08, 2.05) 2.43 0.015 e 2.69 (1.55, 4.68) 3.51 !0.001
Phase I fields 2 655 319 1.22 (0.89, 1.67) 1.24 0.214 e 1.16 (0.82, 1.63) 0.84 0.403
Fractions imaged 0 657 320 1.87 (1.45, 2.40) 4.88 !0.001 e 1.56 (1.38, 1.77) 6.92 !0.001
Baseline bladder symptoms 6 651 319 0.80 (0.58, 1.10) 1.40 0.161 e 0.78 (0.56, 1.10) 1.4 0.161
T-stage and differentiation were not included in the multivariate models because they were jointly represented in the risk group. LMPA,
low melting point alloy; MLC, multileaf collimator; EPI, electronic portal imaging. *Category (reference category is depicted in bold):
T-stage¼ T1 vs T2 vs T3; Differentiation¼Good vs moderate vs poor (based on differentiation or Gleason sum score, where available);
Age¼ 46e62, 63e66, 67e70, 71 and over; Risk group¼ Low vs moderate (trial stratification factor); Allocated treatment¼ 74Gy/37 fractions
vs 64 Gy/32 fractions; Beam modification¼MLC vs LMPA; Treatment verification¼ EPI vs film; Phase I fields¼ three vs four; Total
dose¼!64Gy vs 64 Gyþ; Number of fractions reported¼ 0e3 vs 4e6 vs 7þ.
588 CLINICAL ONCOLOGYfor conformal prostate set-up, enabling developments
within centres. It also showed that there is a considerable
learning and preparation time and a need for ongoing work
to implement new and complex practice, and the need for
appropriate technology and associated user skills to be
available. It is recommended that for future trials involving
technical developments in radiotherapy, a radiographer
group is included and this is being undertaken in the UK as
part of the Academic Clinical Oncology and Radiobiology
Research Network (ACORRN) project [29]. The RTIG forumTable 6 e Patients with one or more displacement of 5 mm in weeks
Category*
Data Univaria
Miss n
3 mmþ
displacement OR (95% CI)
T-stage 2 639 365 1.13 (0.89, 1.44
Differentiation 0 641 366 0.80 (0.58, 1.11
Age (quartile) 0 641 366 1.00 (0.87, 1.16
Risk group 0 641 366 1.40 (1.00, 1.97
Allocated treatment 0 641 366 1.06 (0.78, 1.45
Dose group 0 641 366 0.75 (0.21, 2.61
Beam modification 5 636 363 2.99 (2.09, 4.29
Treatment verification 1 640 366 2.94 (2.10, 4.10
Phase I fields 1 640 366 1.31 (0.95, 1.80
Fractions imaged 0 641 366 3.83 (2.94, 5.00
Baseline toxicity 6 635 366 0.88 (0.64, 1.22
T-stage and differentiation were not included in the multivariate mode
low melting point alloy; MLC, multileaf collimator; EPI, electronic por
T-stage¼ T1 vs T2 vs T3; Differentiation¼Good vs moderate vs poor (
Age¼ 46e62, 63e66, 67e70, 71 and over; Risk group¼ Low vs moderate (
vs 64 Gy/32 fractions; Beam modification¼MLC vs LMPA; Treatment
dose¼!64Gy vs 64 Gyþ; Number of fractions reported¼ 0e3 vs 4e5 vallowed differences in practice to be explored and best
practice was developed [6].
A time trend has been found to be significant in other
much smaller studies [23,30]. This was not tested in this
trial because of the structure of the available data, but the
proportion of imaged fractions associated with a displace-
ment seemed to have decreased over time. However, the
clinical significance of any time trend may be questioned.
Weekly imaging protocols must balance increased radiation
dose and workload with the benefit of accurate treatment3e6: univariate and multivariate logistic regression models
te models Multivariate models
z P n OR (95% CI) z P
) 1.01 0.313 630 e e e e
) 1.35 0.178 e e e e e
) 0.06 0.953 e 0.94 (0.80, 1.11) 0.68 0.493
) 1.94 0.052 e 1.21 (0.81, 1.80) 0.95 0.344
) 0.39 0.698 e 1.06 (0.74, 1.52) 0.31 0.755
) 0.46 0.649 e e e e e
) 5.96 !0.001 e 1.10 (0.60, 2.00) 0.3 0.765
) 6.30 !0.001 e 3.12 (1.77, 5.48) 3.95 !0.001
) 1.65 0.099 e 0.77 (0.52, 1.13) 1.33 0.185
) 9.92 !0.001 e 1.70 (1.52, 1.91) 9.11 !0.001
) 0.76 0.446 e 0.82 (0.56, 1.19) 1.05 0.294
ls because they were jointly represented in the risk group. LMPA,
tal imaging. *Category (reference category is depicted in bold):
based on differentiation or Gleason sum score, where available);
trial stratification factor); Allocated treatment¼ 74Gy/37 fractions
verification¼ EPI vs film; Phase I fields¼ three vs four; Total
s 6e8 vs 9þ.
589REPRODUCIBILITY OF CONFORMAL RADIOTHERAPY IN PROSTATE CANCERassociated with the identification and subsequent correc-
tion of displacements. It also depends on the tolerance
level applied. For a 5 mm tolerance level, the value of
weekly imaging is reduced, but for 3 mm tolerance, weekly
imaging is recommended.
From the (ordered) logistic regression modelling there
was evidence that increased T-stage was associated with
increased R 3 mm displacements reported. We speculate
that patients with more symptomatic advanced cancers
may have had more difficulty in maintaining a full bladder
and therefore increased difficulty in maintaining a stable
position during treatment. A more manageable drinking
protocol of less than 500 ml or treating with an empty
bladder may improve reproducibility, but this would require
further study to assess the effects on small bowel and
bladder toxicity. This category of patients may be consid-
ered unsuitable for further margin reduction techniques
unless image guidance is available.
Beam modification with LMPA rather than MLC was
associated with increased identification of displacement.
The use of LMPA and film may be associated with a longer
overall fraction delivery time, so the likelihood of patient
movement is increased, combining film and LMPA will
compound this effect.
Another consistently important factor was the actual
number of fractions reported during each period. There was
clear evidence in univariate and multivariate models that
an increased number of fractions imaged was statistically
significantly associated with the finding of at least one
displacement. The number of fractions imaged is not an
entirely independent variable; finding displacements or
making corrections required further imaging, affecting the
total number of fractions imaged and possibly the number
of further displacements reported. For these reasons the
models focused on the reporting of one reported displace-
ment or more rather than the actual number of displace-
ments. Future trials recording displacement and correction
data could pre-specify the fractions for imaging, these then
being the primary focus of any analyses of displacement.Conclusions
It is feasible to give accurate and reproducible treatment
according to external measurements of displacement. The
RT01 trial provided a unique opportunity to study the
accuracy of treatment techniques being used for conformal
radiotherapy on a large scale and showed that patient set-
up uncertainties contributed the largest component of the
reported errors. Moderate risk group patients were more
likely to have a displacement O3 mm. The use of EPI and
MLC are associated with fewer displacements reported and
weekly imaging is recommended for departments using
a 3 mm tolerance level for displacement correction. In
future trials where set-up reproducibility is an outcome
measure, it would be advantageous to use specified
fractions to record displacements and to be more pre-
scriptive in the protocol for the correction of errors to
enable random and systematic errors to be assessed.The RTIG was vital to ensuring that the trial protocol was
followed and best practice developed and it is recommen-
ded that such a group is included in future similar trials.
Radiographer-led assessment of treatment verifications has
enabled a UK national multi-centre trial of conformal
prostate radiotherapy to be accomplished with acceptably
high standards of accuracy and reproducibility.
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